Long-Term Follow Up of VOY-101 for Non-Neovascular Age-Related Macular Degeneration
This study is a long-term follow-up for people who previously received an injection of VOY-101 for advanced non-neovascular age-related macular degeneration (AMD). This is an observational study, meaning you won't receive any new treatments as part of this study. Researchers want to understand the long-term safety of VOY-101 by tracking any side effects related to the eye or body for up to 3 years. To join, you must have previously participated in a VOY-101 study (PBI-AMD-001 or PBI-AMD-002). The current status of this study is unclear, and it plans to enroll 88 participants.
- Study design
- This is an observational study, meaning no new treatments are given. It is a long-term follow-up for people who previously received VOY-101, with a planned enrollment of 88 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 3 years to track the frequency of side effects related to VOY-101.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
At a glance
Conditions
Where it's being run
4 sites across 4 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Frequency of ocular and systemic VOY-101 related AEs3 years
Frequency of ocular and systemic VOY-101 related AEs (serious \[SAEs\] and treatment-emergent non-serious adverse events \[TEAEs\]).